These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16550508)

  • 21. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
    Yabe M; Sako M; Yabe H; Osugi Y; Kurosawa H; Nara T; Tokuyama M; Adachi S; Kobayashi C; Yanagimachi M; Ohtsuka Y; Nakazawa Y; Ogawa C; Manabe A; Kojima S; Nakahata T;
    Pediatr Transplant; 2008 Dec; 12(8):862-7. PubMed ID: 18397212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis.
    Sack FU; Kristen A; Goldschmidt H; Schnabel PA; Dengler T; Koch A; Karck M
    Eur J Cardiothorac Surg; 2008 Feb; 33(2):257-62. PubMed ID: 18096396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.
    Mignot A; Bridoux F; Thierry A; Varnous S; Pujo M; Delcourt A; Gombert JM; Goujon JM; Favreau F; Touchard G; Herpin D; Jaccard A
    Haematologica; 2008 Mar; 93(3):e32-5. PubMed ID: 18310532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.
    Komatsu T; Narimatsu H; Yoshimi A; Kurita N; Kusakabe M; Hori A; Murashige N; Matsumura T; Kobayashi K; Yuji K; Tanaka Y; Kami M
    Ann Hematol; 2007 Jan; 86(1):49-54. PubMed ID: 17036221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
    Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
    Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Lachmann HJ; Wechalekar AD; Gillmore JD
    N Engl J Med; 2008 Jan; 358(1):91-2; author reply 92-3. PubMed ID: 18175386
    [No Abstract]   [Full Text] [Related]  

  • 31. High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.
    Narimatsu H; Watanabe M; Kohno A; Sugimoto K; Kuwatsuka Y; Uchida T; Murata M; Miyamura K; Morishita Y;
    Bone Marrow Transplant; 2008 Apr; 41(8):753-6. PubMed ID: 18195683
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
    Madan S; Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Hogan WJ; Leung N; Grogan M; Gertz MA
    Blood; 2012 Feb; 119(5):1117-22. PubMed ID: 22147893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conditioning with fludarabine alone and allogeneic transplantation as a successful rescue therapy for persistent, severe iatrogenic aplasia after relapse of acute myeloid leukemia.
    Lazarevic V; Wahlin A
    Bone Marrow Transplant; 2007 Jan; 39(1):53-4. PubMed ID: 17115065
    [No Abstract]   [Full Text] [Related]  

  • 39. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.
    Mollee PN; Wechalekar AD; Pereira DL; Franke N; Reece D; Chen C; Stewart AK
    Bone Marrow Transplant; 2004 Feb; 33(3):271-7. PubMed ID: 14647248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term survival after autologous peripheral blood stem cell transplantation in a patient with primary AL amyloidosis complicating congestive heart failure].
    Saito M; Hayashi T; Nojima M; Ikeda H; Tarasawa I; Yasui H; Ishida T; Adachi M; Imai K; Shinomura Y
    Rinsho Ketsueki; 2007 Nov; 48(11):1478-83. PubMed ID: 18080505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.